Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavorixafor + Toripalimab in Advanced TNBC
NCT05103917Phase 2Unknown
- Sponsor
- Abbisko Therapeutics
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavorixafor in triple-negative breast cancer (TNBC), sponsored by Abbisko Therapeutics. Primary endpoint: Safety and Tolerability. Status: unknown.
02
Drugs
mavorixafor
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05103917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103917.